The respective model repository can be found in:
https://github.com/Open-Systems-Pharmacology/Atazanavir-Raltegravir-DDI

The atazanavir / raltegravir interaction was evaluated using four clinical DDI studies ([Iwamoto 2008](#4-References), [Krishna 2008](#4-References), [Neely 2010](#4-References), [Zhu 2010](#4-References)).



| Enzyme | Perpetrator / victim     | Study design                                                 | Clinical study                 |
| ------ | ------------------------ | ------------------------------------------------------------ | ------------------------------ |
| UGT1A1 | Atazanavir / raltegravir | Atazanavir: 400 mg once daily dosing<br />Raltegravir: 100 mg single dose on day 7 simultaneous with the 7th dose of atazanavir | [Iwamoto 2008](#4-References)  |
| UGT1A1 | Atazanavir / raltegravir | Atazanavir: 400 mg once daily dosing<br />Raltegravir: 1200 mg single dose on day 7 simultaneous with the 7th dose of atazanavir | [Krishna 2008,](#4-References) |
| UGT1A1 | Atazanavir / raltegravir | Atazanavir: 400 mg once daily dosing<br />Raltegravir: 400 mg once daily dosing (control phase 400 mg twice daily)<br />DDI assessment on day 8 | [Neely 2010](#4-References)    |
| UGT1A1 | Atazanavir / raltegravir | Atazanavir: 300 mg twice daily dosing<br />Raltegravir: 400 mg twice daily dosing <br />DDI assessment on day 27 | [Zhu 2010](#4-References)      |

